Pfeil nach linksPfeil nach rechts

Charlotte Zajc

Dr. Charlotte Zajc
Status Currently not employed at BOKU

ORCID: 0000-0002-9356-7430

classifications according to Statistics Austria Biochemistry Medical biochemistry Gene therapy Cell therapy

Research Focus

Cellular cancer immunotherapies, CAR T cells, Protein Engineering, signal transduction in CAR T cells

free keywords CAR T cells Cellular Therapies Protein Engineering

 

Career

  • 2024 Senor Postdoc
  • 2022 - 2023 Maternity leave
  • 2020 - 2024 Postdoc (Department of Chemistry, BOKU, CD Lab for next generation CAR T cells)
  • 2018 - 2019 Research stay at Stanford School of Medicine
  • 2016 - 2020 PhD student at the St.Anna Children´s Cancer Research Institute
  • 2015 - 2016 Master thesis at the St. Anna Children´s Cancer Research Institute
  • 2013 - 2015 Master studies „Biotechnology“ (University of Natural Resources and Life Sciences)
  • 2008 - 2013 Bachelorstudies "Food- and Biotechnology" (University of Natural Resources and Life Sciences)

Awards

  • Year: 2023 Awards: For Women in Science Fellowship L´Oreal & UNESCO Austria
  • Year: 2021 Awards: Life Science Research Award, ÖGMBT
  • Year: 2020 Awards: BOKU Best Paper Award
  • Year: 2020 Awards: BOKU Erfindung des Jahres 2020
  • Year: 2020 Awards: BOKU Talent Award

Projects

0 Projects found.

filter result: categorie

    Publications

    Knowledge Transfer to Society

    Media

    Lectures

    • Year: 2024 -  Engineering of molecular ON- and OFF-switches for controlling CAR T cells

      Autoren: Zajc, CU; Sumesgutner, D; Mayer, J; Sylvander, E; Teufl, M; Traxlmayr, MW

      Event: EBMT-EHA 6th European CAR T-cell Meeting

    • Year: 2023 -  Unraveling the FMC63-CD19 affinity

      Autoren: Seigner, J; Zajc, CU; Dötsch, S; Eigner, C; Laurent, E; Busch, DH; Lehner, M; Traxlmayr, MW

      Event: Keystone meeting on Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy

    • Year: 2023 -  Engineering molecular switches for functional control of CAR T cells with an orally available small molecule drug.

      Autoren: Zajc, CU; Dobersberger, M; Schaffner, I; Mlynek, G; Pühringer, D; Salzer, B; Djinović-Carugo, K; Obinger, C; Lehner, M; Traxlmayr, MW

      Event: EHA-EBMT 5th European CAR T-cell Meeting

    • Year: 2023 -  Taking control of CAR T cells- Engineering of molecular ON-switches for cellular therapies

      Autoren: Charlotte U. Zajc, Markus Dobersberger, Manfred Lehner and Michael W. Traxlmayr

      Event: ÖGMBT Annual Meeting

    • Year: 2020 -  A conformation-specific ON-switch for controlling CAR T cells with an orally available drug

      Autoren: Brey, C.U.; Dobersberger, M.; Schaffner, I.; Salzer, B.; Obinger, C.; Holter, W.; Traxlmayr, M.W.; Lehner, M.

      Event: Keystone-Emerging cellular therapies

    Supervised Theses

    Community Services